Global Mycoplasma Testing Market Size (2024 - 2029)

The mycoplasma testing market is anticipated to experience significant growth, driven by increased research and development investments, government funding, and technological advancements. The demand for rapid and accurate testing solutions, along with the rising incidence of cell culture contamination, further propels the market. The easing of COVID-19 restrictions is expected to contribute to the resurgence of mycoplasma-related infections, thereby influencing market expansion. However, stringent regulatory environments and high market consolidation pose challenges to new entrants, potentially impacting the overall market size.

Market Size of Global Mycoplasma Testing Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Mycoplasma Testing Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 13.00 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Mycoplasma Testing Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Mycoplasma Testing Market Analysis

The mycoplasma testing market is estimated to register a healthy CAGR of 13% over the forecast period, 2022-2027.

In recent times, countries have faced a huge threat of COVID-19. As per the World Health Organization (WHO), coronavirus disease is an infectious disease, and most people infected with the COVID-19 virus will experience mild to moderate respiratory illness. The study "The Prevalence of Mycoplasma Pneumoniae Among Children in Beijing Before and During the COVID-19 Pandemic" published in April 2022, stated that the M. pneumoniae outbreak started in the summer of 2019 in Beijing. After the COVID-19 pandemic outbreak at the end of 2019, the M. pneumoniae positive rates dropped dramatically. This was due to the restrictive measures of the COVID-19 pandemic, which effectively controlled the transmission of M. pneumonia. However, after the easing of COVID-19 restrictions, M. pneumonia is expected to increase further during the study period, thereby impacting the market growth.

Factors such as high spending in R&D activities by biopharmaceutical companies, increased government initiatives and funding in research activities, technological advancements, increasing demand for fast, accurate, and affordable testing, and the increasing cell culture contamination, are further driving the market for mycoplasma testing.

The study "Point-of-care molecular diagnosis of Mycoplasma pneumonia including macrolide sensitivity using quenching probe polymerase chain reaction" published in October 2021, stated that the Smart Gene system is a rapid and accurate assay for detection of the existence of M. pneumoniae and a point mutation at domain V of the 23S rRNA gene of M. pneumoniae at the same time. The Smart Gene system is suitable for point-of-care testing in both hospital and outpatient settings. Thus, such studies indicating the potential of diagnostic testing for mycoplasma pneumonia will increase their acceptance, thus driving the market.

In April 2022, AlphaBiolabs launched STI testing for members of the public and healthcare partners. The Complete Panel (7 STIs) detects chlamydia, gonorrhea, mycoplasma genitalium, mycoplasma hominis, trichomoniasis, and ureaplasma parvum (UTI), and urea urealyticum (UTI) bacterias. Therefore, the launch of such tests detecting mycoplasma bacteria will boost the market. Thus, due to the above-mentioned factors, the studied market is expected to grow significantly during the study period. However, there are certain stringent government regulations across several developed and emerging countries and a high degree of consolidation for new entrants, which are among the major hindrances in the growth of the mycoplasma testing market.

Mycoplasma Testing Industry Segmentation

The term 'mycoplasma' refers to a class of bacteria commonly present in cell culture. More correctly known as mollicutes, these bacteria lack a cell wall, making them resistant to commonly used antibiotics, such as penicillin. Mycoplasma is easily spread through droplets during cell culture and can survive in dried form for months. Mycoplasma contamination is difficult to see with a microscope and requires specific testing to be detected. Contamination can have a profound impact on experimental work. The mycoplasma testing market is segmented by technology (PCR, ELISA, enzymatic methods, DNA staining, and other technologies), product (instruments, kits, and reagents), application (cell line testing, bioproduction testing, and other applications), and geography (North America, Europe, Asia - Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product
Instruments
Kits and Reagents
By Technology
PCR
ELISA
Enzymatic Methods
DNA Staining
Other Technologies
By Application
Cell Line Testing
Bioproduction Testing
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Mycoplasma Testing Market Size Summary

The mycoplasma testing market is poised for significant growth, driven by factors such as increased research and development investments by biopharmaceutical companies, government initiatives, and technological advancements. The demand for rapid, accurate, and cost-effective testing solutions is on the rise, fueled by the growing incidence of cell culture contamination. The market is further bolstered by innovations in diagnostic testing, such as the Smart Gene system, which offers point-of-care testing capabilities. The launch of comprehensive testing panels by companies like AlphaBiolabs is expected to enhance market penetration. However, the market faces challenges from stringent regulatory environments and high consolidation rates, which may impede the entry of new players.

North America currently leads the mycoplasma testing market, with a stronghold expected to continue due to its robust healthcare infrastructure and increasing prevalence of respiratory diseases. The region benefits from the presence of global biotech and pharmaceutical companies, alongside substantial investments in research and development. The United States, in particular, holds a significant market share, supported by rising healthcare expenditures and the swift adoption of point-of-care testing. The introduction of innovative products, such as bioMérieux's BIOFIRE MYCOPLASMA, and strategic expansions by companies like Infinity Laboratories are contributing to market growth. The competitive landscape is characterized by key players engaging in new product launches, collaborations, and acquisitions to strengthen their market presence.

Explore More

Global Mycoplasma Testing Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increased Government Initiatives and Funding in Research Activities

      2. 1.2.2 Increasing Demand for Fast, Accurate, and Affordable Testing

      3. 1.2.3 Increasing Cell Culture Contamination

    3. 1.3 Market Restraints

      1. 1.3.1 Long and Laborious Detection Process

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - in USD Million)

    1. 2.1 By Product

      1. 2.1.1 Instruments

      2. 2.1.2 Kits and Reagents

    2. 2.2 By Technology

      1. 2.2.1 PCR

      2. 2.2.2 ELISA

      3. 2.2.3 Enzymatic Methods

      4. 2.2.4 DNA Staining

      5. 2.2.5 Other Technologies

    3. 2.3 By Application

      1. 2.3.1 Cell Line Testing

      2. 2.3.2 Bioproduction Testing

      3. 2.3.3 Other Applications

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Mycoplasma Testing Market Size FAQs

The Global Mycoplasma Testing Market is projected to register a CAGR of 13% during the forecast period (2024-2029)

Bionique Testing Laboratories Inc., Thermo Fisher Scientific Inc., Eurofins Scientific, Merck KGaA and ATCC are the major companies operating in the Global Mycoplasma Testing Market.

Mycoplasma Testing Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)